Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Castration-resistant Prostate Cancer 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 3Oncolytic Virotherapy 3Magnetic Resonance Spectroscopy 3Specimen Handling 2Radiotherapy 2Nivolumab 2Irinotecan 2Doxorubicin 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1pertuzumab 1perflutren 1palbociclib 1olaparib 1niraparib 1montelukast 1eribulin 1entrectinib 1cobimetinib 1camrelizumab 1atezolizumab 1apatinib 1alovudine 1alectinib 1X-Rays 1Vinorelbine 1Vincristine 1Vemurafenib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Sarcoma × alovudine × Clear all
NCT03613259 2020-06-09

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡